TY - GEN A1 - Frost, Fabian A1 - Weiss, Stefan A1 - Hertel, Johannes A1 - Rühlemann, Malte A1 - Bang, Corinna A1 - Franke, Andre A1 - Nauck, Matthias A1 - Dörr, Marcus A1 - Völzke, Henry A1 - Roggenbuck, Dirk A1 - Schierack, Peter A1 - Völker, Uwe A1 - Homuth, Georg A1 - Aghdassi, Ali A. A1 - Sendler, Matthias A1 - Lerch, Markus M. A1 - Weiss, Frank U. T1 - Fecal glycoprotein 2 is a marker of gut microbiota dysbiosis and systemic inflammation T2 - Gut Pathogens N2 - Background autoantigenic glycoprotein 2 (GP2) is an important component of the innate immune system which originates from the exocrine pancreas as well as from the small intestines. The relationship of GP2 with the intestinal microbiome as well as the systemic implications of increased fecal GP2 levels are, however, still unclear. Therefore, fecal samples from 2,812 individuals of the Study of Health in Pomerania (SHIP) were collected to determine GP2 levels (enzyme-linked immunosorbent assay) and gut microbiota profiles (16 S rRNA gene sequencing). These data were correlated and associated with highly standardised and comprehensive phenotypic data of the study participants. Results Fecal GP2 levels were increased in individuals with higher body mass index and smokers, whereas lower levels were found in case of preserved exocrine pancreatic function, female sex or a healthier diet. Moreover, higher GP2 levels were associated with increased serum levels of high-sensitivity C-reactive protein, loss of gut microbial diversity and an increase of potentially detrimental bacteria (Streptococcus, Haemophilus, Clostridium XIVa, or Collinsella). At the same time, predicted microbial pathways for the biosynthesis of beneficial short-chain fatty acids or lactic acid were depleted in individuals with high fecal GP2. Of note, GP2 exhibited a stronger association to overall microbiome variation than calprotectin. Conclusion Fecal GP2 is a biomarker of gut microbiota dysbiosis and associated with increased systemic inflammation. The intestines may be more important as origin for GP2 than pancreatic acinar cells. Future studies need to investigate the potential clinical value in disease specific patient cohorts. Y1 - 2024 U6 - https://doi.org/10.1186/s13099-024-00657-1 SN - 1757-4749 VL - 16 IS - 1 SP - 1 EP - 11 PB - Springer Science and Business Media LLC ER - TY - GEN A1 - Lopens, Steffi A1 - Schierack, Peter A1 - Krause, Jenny A1 - Piaszczyński, Michał A1 - Król, Robert A1 - Staroń, Robert A1 - Krupa, Łukasz A1 - Gutkowski, Krzysztof A1 - Kruk, Beata A1 - Grąt, Michał A1 - Krawczyk, Marek A1 - Patkowski, Waldemar A1 - Glaser, Fabian A1 - Rödiger, Stefan A1 - Grossmann, Kai A1 - Pająk, Jacek A1 - Milkiewicz, Piotr A1 - Lammert, Frank A1 - Zieniewicz, Krzysztof A1 - Schramm, Christoph A1 - Roggenbuck, Dirk A1 - Krawczyk, Marcin T1 - Antimicrobial glycoprotein 2 (GP2) in gallstones, bile fluid and peribiliary glands of patients with primary sclerosing cholangitis T2 - Clinica Chimica Acta Y1 - 2024 U6 - https://doi.org/10.1016/j.cca.2024.119841 SN - 0009-8981 VL - 562 SP - 1 EP - 8 PB - Elsevier BV ER -